Shanghai RAAS Blood Products (002252.SZ) plans to acquire 100% equity of Boehringer Ingelheim Biopharmaceuticals.

Shanghai RAAS Blood Products (002252.SZ) announced that the company plans to acquire, by way of cash, 100% equity of Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. (the "Target Company") held by Boehringer Ingelheim (China) Investment Co., Ltd., with the expected acquisition price not exceeding RMB 20 million. Upon completion of the transaction, the Target Company will become a wholly-owned subsidiary of the company. It is understood that the Target Company, relying on a mammalian cell technology platform, is primarily engaged in contract development and manufacturing of biopharmaceuticals, providing production supply from clinical to commercial stages for innovative biopharmaceutical companies globally and in China, and covering professional technical services such as CMC regulatory support, analytical method development and validation. The Target Company has established a biopharmaceutical contract manufacturing base with a 6,000L commercial-scale production capacity. This acquisition is an important layout for the company to implement its medium- and long-term strategy and shore up shortcomings in the industrialization of innovative drugs. The company intends to obtain the Target Company's mature production capacity, standardized quality control system, and professional technical team, so as to ensure the stable and on-schedule production and launch of its core product SR604 and subsequent innovative drugs, accelerate the translation of the company's innovative drug pipeline achievements, and solidify the industrial foundation for the company's second growth curve.